デフォルト表紙
市場調査レポート
商品コード
1589208

クリティカルケア診断薬市場:検査別、エンドユーザー別-2025-2030年の世界予測

Critical Care Diagnostics Market by Test (Coagulation Testing, Flow Cytometry, Hematology), End-User (Emergency Rooms, Intensive Care Units, Operation Rooms) - Global Forecast 2025-2030


出版日
発行
360iResearch
ページ情報
英文 197 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.91円
クリティカルケア診断薬市場:検査別、エンドユーザー別-2025-2030年の世界予測
出版日: 2024年10月31日
発行: 360iResearch
ページ情報: 英文 197 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

クリティカルケア診断薬市場は、2023年に12億3,000万米ドルと評価され、2024年には14億5,000万米ドルに達すると予測され、CAGR 17.97%で成長し、2030年には39億1,000万米ドルに達すると予測されています。

クリティカルケア診断薬では、ICUや救急部などのクリティカルケア環境において、生命を脅かす状態を診断し、治療をモニタリングするための技術的ツールや機器の使用が含まれます。この分野には、血液分析装置、画像診断装置、分子診断装置など幅広い検査や機器が含まれ、重篤な疾患や傷害に対する迅速な意思決定と効果的な管理に不可欠です。クリティカルケア診断薬の必要性は、慢性および急性の病状がますます蔓延し、世界の高齢化も相まって、迅速で正確な診断ソリューションへの需要が高まっていることからも明らかです。その用途は、敗血症や肺炎の早期発見から重要な臓器機能のモニタリングまで多岐にわたる。エンドユーザーには主に病院、診療所、診断センターが含まれ、効率的で信頼性の高い診断オプションを求め続けています。

主な市場の統計
基準年[2023] 12億3,000万米ドル
予測年[2024] 14億5,000万米ドル
予測年[2030] 39億1,000万米ドル
CAGR(%) 17.97%

この市場に影響を与える主な成長要因には、診断ツールの技術的進歩、医療費の増加、患者中心のケアへの注目の高まりなどがあり、自動診断と個別化治療戦略のための人工知能と機械学習の統合における機会が強調されています。新興国は、ヘルスケア・インフラの改善とヘルスケア・サービスへの投資の増加により、潜在的な成長機会をもたらしています。しかし、高度な診断機器の高コスト、熟練した人材の不足、厳しい規制の枠組みといった課題は、市場の成長を阻害する可能性があります。また、異なる診断機器の相互運用性の問題からも限界が生じ、標準化の取り組みが必要となります。

イノベーション分野の開拓が必要な分野には、医療施設の負担を大幅に軽減し、アクセシビリティを向上させるポータブル診断機器やポイントオブケア診断機器の開発が含まれます。非侵襲的診断技術や遠隔医療統合などのデジタルヘルスソリューションの調査は、市場浸透の強化につながるものと期待されます。市場は競争が激しく、急速な技術革新と絶え間ないイノベーションが特徴です。卓越を目指す企業は、戦略的パートナーシップの形成、研究開発への投資、製品ポートフォリオの拡充に注力し、クリティカルケア診断薬の進化するニーズに応えるべきです。

市場力学:急速に進化するクリティカルケア診断薬市場の主要市場インサイトを公開

クリティカルケア診断薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

  • 市場促進要因
    • 世界の老人人口の増加と慢性疾患の流行
    • 迅速な診断と治療に対する需要の高まり
    • データ管理と電子カルテ(EHR)への接続性の成長
  • 市場抑制要因
    • 診断ツールの高コスト
  • 市場機会
    • 政府の活動および導入支援クリティカルケア診断薬
    • 診断機器と検査室間の遠隔通信の増加
  • 市場の課題
    • 熟練した専門家の不足

ポーターの5つの力:クリティカルケア診断薬市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析:クリティカルケア診断薬市場における外部からの影響の把握

外部マクロ環境要因は、クリティカルケア診断薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析クリティカルケア診断薬市場における競合情勢の把握

クリティカルケア診断薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスクリティカルケア診断薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、クリティカルケア診断薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨クリティカルケア診断薬市場における成功への道筋を描く

クリティカルケア診断薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています:

1.市場の浸透度:現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度:新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化:最近の製品上市、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報:競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション:将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています:

1.現在の市場規模と今後の成長予測は?

2.最高の投資機会を提供する製品、セグメント、地域はどこか?

3.市場を形成する主な技術動向と規制の影響とは?

4.主要ベンダーの市場シェアと競合ポジションは?

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か?

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 世界中で増加する高齢者人口と慢性疾患の蔓延
      • 迅速な診断と治療の需要の増加
      • データ管理と電子健康記録(EHR)への接続性の向上
    • 抑制要因
      • 診断ツールの高コスト
    • 機会
      • 政府の活動とクリティカルケア診断薬の実施支援
      • 診断と検査室間の遠隔通信の増加
    • 課題
      • 熟練した専門家の不足
  • 市場セグメンテーション分析
  • ポーターのファイブフォース分析
  • PESTEL分析
    • 政治的
    • 経済
    • 社交
    • 技術的
    • 法律上
    • 環境

第6章 クリティカルケア診断薬市場テスト別

  • 凝固検査
  • フローサイトメトリー
  • 血液学
  • 免疫タンパク質
  • 微生物および感染症
  • 日常化学と特殊化学

第7章 クリティカルケア診断薬市場:エンドユーザー別

  • 救急室
  • 集中治療室
  • 手術室

第8章 南北アメリカのクリティカルケア診断薬市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第9章 アジア太平洋地域のクリティカルケア診断薬市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第10章 欧州・中東・アフリカのクリティカルケア診断薬市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第11章 競合情勢

  • 市場シェア分析2023
  • FPNVポジショニングマトリックス, 2023
  • 競合シナリオ分析
  • 戦略分析と提言

企業一覧

  • Abbott Laboratories
  • Bayer Healthcare AG
  • Becton, Dickinson & Company
  • Danaher Corporation
  • EKF Diagnostics Holdings PLC
  • F. Hoffmann-La Roche AG
  • General Electric Company
  • HORIBA, Ltd.
  • Johnson and Johnson Service, Inc.
  • Medcaptain Medical Technology Co., Ltd
  • Medtronic PLC
  • Omron Corporation
  • Roche Diagnostics Ltd.
  • Sysmex Corporation
  • WerfenLife, S.A.
図表

LIST OF FIGURES

  • FIGURE 1. CRITICAL CARE DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. CRITICAL CARE DIAGNOSTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CRITICAL CARE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. CRITICAL CARE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. CRITICAL CARE DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CRITICAL CARE DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CRITICAL CARE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CRITICAL CARE DIAGNOSTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY COAGULATION TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY IMMUNOPROTEINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY MICROBIAL & INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY ROUTINE & SPECIAL CHEMISTRY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY EMERGENCY ROOMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY INTENSIVE CARE UNITS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY OPERATION ROOMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 23. BRAZIL CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 25. CANADA CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 26. CANADA CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 27. MEXICO CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 28. MEXICO CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 29. UNITED STATES CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 30. UNITED STATES CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. UNITED STATES CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 32. ASIA-PACIFIC CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 33. ASIA-PACIFIC CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. ASIA-PACIFIC CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 35. AUSTRALIA CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 36. AUSTRALIA CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. CHINA CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 38. CHINA CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. INDIA CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 40. INDIA CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. INDONESIA CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 42. INDONESIA CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. JAPAN CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 44. JAPAN CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. MALAYSIA CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 46. MALAYSIA CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. PHILIPPINES CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 48. PHILIPPINES CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 49. SINGAPORE CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 50. SINGAPORE CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. SOUTH KOREA CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 52. SOUTH KOREA CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. TAIWAN CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 54. TAIWAN CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 55. THAILAND CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 56. THAILAND CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. VIETNAM CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 58. VIETNAM CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 60. EUROPE, MIDDLE EAST & AFRICA CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. EUROPE, MIDDLE EAST & AFRICA CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 62. DENMARK CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 63. DENMARK CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 64. EGYPT CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 65. EGYPT CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. FINLAND CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 67. FINLAND CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. FRANCE CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 69. FRANCE CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 70. GERMANY CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 71. GERMANY CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. ISRAEL CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 73. ISRAEL CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. ITALY CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 75. ITALY CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 76. NETHERLANDS CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 77. NETHERLANDS CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. NIGERIA CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 79. NIGERIA CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. NORWAY CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 81. NORWAY CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 82. POLAND CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 83. POLAND CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. QATAR CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 85. QATAR CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. RUSSIA CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 87. RUSSIA CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. SAUDI ARABIA CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 89. SAUDI ARABIA CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH AFRICA CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH AFRICA CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 92. SPAIN CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 93. SPAIN CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. SWEDEN CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 95. SWEDEN CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. SWITZERLAND CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 97. SWITZERLAND CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 98. TURKEY CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 99. TURKEY CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED ARAB EMIRATES CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED ARAB EMIRATES CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED KINGDOM CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 103. UNITED KINGDOM CRITICAL CARE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 104. CRITICAL CARE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 105. CRITICAL CARE DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023
目次
Product Code: MRR-807A20B5CC5E

The Critical Care Diagnostics Market was valued at USD 1.23 billion in 2023, expected to reach USD 1.45 billion in 2024, and is projected to grow at a CAGR of 17.97%, to USD 3.91 billion by 2030.

Critical care diagnostics involves the use of technological tools and equipment to diagnose life-threatening conditions and monitor treatment in critical care settings, such as ICUs and emergency departments. This field encompasses a wide range of tests and devices, including blood analyzers, imaging equipment, and molecular diagnostics, which are essential for swift decision-making and effective management of severe illnesses or injuries. The necessity of critical care diagnostics is underscored by the increasing prevalence of chronic and acute medical conditions, coupled with the aging global population, which heightens the demand for rapid and accurate diagnostic solutions. Their application spans from early detection of sepsis and pneumonia to monitoring vital organ functions, thereby enhancing patient care and outcomes. End users primarily include hospitals, clinics, and diagnostic centers, which continually seek efficient and reliable diagnostic options.

KEY MARKET STATISTICS
Base Year [2023] USD 1.23 billion
Estimated Year [2024] USD 1.45 billion
Forecast Year [2030] USD 3.91 billion
CAGR (%) 17.97%

Key growth factors influencing this market include technological advancements in diagnostic tools, increasing healthcare expenditure, and a heightened focus on patient-centric care, highlighting opportunities in the integration of artificial intelligence and machine learning for automated diagnostics and personalized treatment strategies. Emerging economies present potential growth opportunities due to improving healthcare infrastructure and increased investments in healthcare services. However, challenges like high costs of advanced diagnostic devices, a lack of skilled personnel, and stringent regulatory frameworks can impede market growth. Limitations also arise from interoperability issues of different diagnostic devices, necessitating standardization efforts.

Innovation areas ripe for exploration include the development of portable and point-of-care diagnostic devices, which can significantly alleviate burdens on healthcare facilities and improve accessibility. Research into non-invasive diagnostic techniques and digital health solutions, such as telemedicine integration, holds promise for enhanced market penetration. The market is competitive, characterized by rapid technological changes and continuous innovation. Companies looking to excel should focus on forming strategic partnerships, investing in R&D, and expanding their product portfolios to cater to the evolving needs of critical care diagnostics.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Critical Care Diagnostics Market

The Critical Care Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising geriatric population worldwide and prevalence of chronic diseases
    • Increasing demand for rapid diagnosis and treatment
    • Growth in data management and connectivity to Electronic Health Record (EHR)
  • Market Restraints
    • High cost of diagnostics tools
  • Market Opportunities
    • Government activities and support for implementing critical care diagnostics
    • Rising remote communications between diagnostics and laboratories
  • Market Challenges
    • Lack of Skilled Professionals

Porter's Five Forces: A Strategic Tool for Navigating the Critical Care Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Critical Care Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Critical Care Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Critical Care Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Critical Care Diagnostics Market

A detailed market share analysis in the Critical Care Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Critical Care Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Critical Care Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Critical Care Diagnostics Market

A strategic analysis of the Critical Care Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Critical Care Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Bayer Healthcare AG, Becton, Dickinson & Company, Danaher Corporation, EKF Diagnostics Holdings PLC, F. Hoffmann-La Roche AG, General Electric Company, HORIBA, Ltd., Johnson and Johnson Service, Inc., Medcaptain Medical Technology Co., Ltd, Medtronic PLC, Omron Corporation, Roche Diagnostics Ltd., Sysmex Corporation, and WerfenLife, S.A..

Market Segmentation & Coverage

This research report categorizes the Critical Care Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Test, market is studied across Coagulation Testing, Flow Cytometry, Hematology, Immunoproteins, Microbial & Infectious Diseases, and Routine & Special Chemistry.
  • Based on End-User, market is studied across Emergency Rooms, Intensive Care Units, and Operation Rooms.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising geriatric population worldwide and prevalence of chronic diseases
      • 5.1.1.2. Increasing demand for rapid diagnosis and treatment
      • 5.1.1.3. Growth in data management and connectivity to Electronic Health Record (EHR)
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of diagnostics tools
    • 5.1.3. Opportunities
      • 5.1.3.1. Government activities and support for implementing critical care diagnostics
      • 5.1.3.2. Rising remote communications between diagnostics and laboratories
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of Skilled Professionals
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Critical Care Diagnostics Market, by Test

  • 6.1. Introduction
  • 6.2. Coagulation Testing
  • 6.3. Flow Cytometry
  • 6.4. Hematology
  • 6.5. Immunoproteins
  • 6.6. Microbial & Infectious Diseases
  • 6.7. Routine & Special Chemistry

7. Critical Care Diagnostics Market, by End-User

  • 7.1. Introduction
  • 7.2. Emergency Rooms
  • 7.3. Intensive Care Units
  • 7.4. Operation Rooms

8. Americas Critical Care Diagnostics Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Critical Care Diagnostics Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Critical Care Diagnostics Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Bayer Healthcare AG
  • 3. Becton, Dickinson & Company
  • 4. Danaher Corporation
  • 5. EKF Diagnostics Holdings PLC
  • 6. F. Hoffmann-La Roche AG
  • 7. General Electric Company
  • 8. HORIBA, Ltd.
  • 9. Johnson and Johnson Service, Inc.
  • 10. Medcaptain Medical Technology Co., Ltd
  • 11. Medtronic PLC
  • 12. Omron Corporation
  • 13. Roche Diagnostics Ltd.
  • 14. Sysmex Corporation
  • 15. WerfenLife, S.A.